While direct-to-patient distribution is a key component of decentralised trials and use continues to grow within protocol designs, many sponsors are encountering challenges around its implementation.
![](https://static.wixstatic.com/media/04ef19_f2729de4f04b4aee95b48b9d13ad73bf~mv2.jpg/v1/fill/w_147,h_83,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_auto/04ef19_f2729de4f04b4aee95b48b9d13ad73bf~mv2.jpg)
While direct-to-patient distribution is a key component of decentralised trials and use continues to grow within protocol designs, many sponsors are encountering challenges around its implementation.